JP2021531754A5 - - Google Patents
Info
- Publication number
- JP2021531754A5 JP2021531754A5 JP2021500735A JP2021500735A JP2021531754A5 JP 2021531754 A5 JP2021531754 A5 JP 2021531754A5 JP 2021500735 A JP2021500735 A JP 2021500735A JP 2021500735 A JP2021500735 A JP 2021500735A JP 2021531754 A5 JP2021531754 A5 JP 2021531754A5
- Authority
- JP
- Japan
- Prior art keywords
- fusion protein
- protein according
- seq
- acid sequence
- amino acid
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025002212A JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862695623P | 2018-07-09 | 2018-07-09 | |
| US201862695627P | 2018-07-09 | 2018-07-09 | |
| US62/695,623 | 2018-07-09 | ||
| US62/695,627 | 2018-07-09 | ||
| US201962863710P | 2019-06-19 | 2019-06-19 | |
| US62/863,710 | 2019-06-19 | ||
| US201962864367P | 2019-06-20 | 2019-06-20 | |
| US62/864,367 | 2019-06-20 | ||
| US201962866420P | 2019-06-25 | 2019-06-25 | |
| US62/866,420 | 2019-06-25 | ||
| PCT/US2019/041085 WO2020014285A2 (en) | 2018-07-09 | 2019-07-09 | Fusion constructs and methods of using thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002212A Division JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021531754A JP2021531754A (ja) | 2021-11-25 |
| JP2021531754A5 true JP2021531754A5 (https=) | 2022-07-08 |
| JPWO2020014285A5 JPWO2020014285A5 (https=) | 2022-07-08 |
| JP7617839B2 JP7617839B2 (ja) | 2025-01-20 |
Family
ID=69141640
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021500735A Active JP7617839B2 (ja) | 2018-07-09 | 2019-07-09 | 融合構築物およびその使用法 |
| JP2025002212A Pending JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025002212A Pending JP2025063123A (ja) | 2018-07-09 | 2025-01-07 | 融合構築物およびその使用法 |
Country Status (11)
| Country | Link |
|---|---|
| US (2) | US11535669B2 (https=) |
| EP (1) | EP3820496A4 (https=) |
| JP (2) | JP7617839B2 (https=) |
| KR (1) | KR20210042909A (https=) |
| CN (2) | CN112672753B (https=) |
| AU (1) | AU2019301070B2 (https=) |
| CA (1) | CA3105750A1 (https=) |
| IL (1) | IL279965A (https=) |
| SG (1) | SG11202100208VA (https=) |
| WO (1) | WO2020014285A2 (https=) |
| ZA (2) | ZA202100390B (https=) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11629340B2 (en) | 2017-03-03 | 2023-04-18 | Obsidian Therapeutics, Inc. | DHFR tunable protein regulation |
| EP3697438A4 (en) * | 2017-10-18 | 2021-08-18 | Intrexon Corporation | POLYPEPTIDE COMPOSITIONS WITH SPACERS |
| BR112021012027A2 (pt) * | 2018-12-21 | 2021-11-03 | Ose Immunotherapeutics | Molécula bifuncional direcionada contra pd-1 humano |
| CN110734498A (zh) * | 2019-10-15 | 2020-01-31 | 上海科棋药业科技有限公司 | 一种用于解除免疫抑制的融合蛋白及其应用 |
| US11802145B2 (en) | 2019-10-21 | 2023-10-31 | Nanjing Leads Biolabs Co., Ltd. | Recombinant protein targeting PD-1 and TGFß |
| EP4051279A1 (en) | 2019-11-01 | 2022-09-07 | Ares Trading S.A. | COMBINED INHIBITION OF PD-1, TGFß AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCER |
| EP4054633A1 (en) | 2019-11-05 | 2022-09-14 | Merck Patent GmbH | Combined inhibition of pd-1, tgfb and tigit for the treatment of cancer |
| CN115397973A (zh) * | 2020-01-30 | 2022-11-25 | 免疫生物公司 | 表达car的nk细胞消除bcma阳性恶性肿瘤 |
| KR20220107257A (ko) * | 2020-03-20 | 2022-08-02 | 레메젠 코, 리미티드 | 이중특이성 융합 단백질 및 그의 응용 |
| AU2021256925A1 (en) | 2020-04-14 | 2022-11-03 | Ares Trading S.A. | Combination treatment for cancer based upon an ICOS antibody and a PD-L1 antibody TGF-beta-receptor fusion protein |
| WO2021209458A1 (en) | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| US20230235057A1 (en) * | 2020-04-29 | 2023-07-27 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Bifunctional protein against pd-1 and tgf-beta |
| WO2021231773A1 (en) | 2020-05-13 | 2021-11-18 | Good Therapeutics, Inc. | Compositions of protein complexes and methods of use thereof |
| CN113754771A (zh) * | 2020-06-02 | 2021-12-07 | 三生国健药业（上海）股份有限公司 | 一种抗pdl1×egfr的双特异性抗体 |
| MX2023000005A (es) * | 2020-06-26 | 2023-03-06 | Sorrento Therapeutics Inc | Virus del herpes simple (vhs) oncolíticos que expresan proteínas de fusión inmunomoduladoras. |
| EP4178680A4 (en) * | 2020-07-10 | 2024-07-31 | Precigen, Inc. | FUSION CONSTRUCTS AND THEIR METHODS OF USE |
| WO2022063314A1 (zh) * | 2020-09-28 | 2022-03-31 | 上海君实生物医药科技股份有限公司 | 靶向PD-1或PD-L1和TGF-β的双功能蛋白及其医药用途 |
| WO2022090527A1 (en) | 2020-11-02 | 2022-05-05 | Ares Trading S.A. | Combination treatment of cancer |
| US20230372319A1 (en) | 2020-11-02 | 2023-11-23 | Ares Trading S.A. | Combination Treatment of Cancer |
| US20230416394A1 (en) * | 2020-11-27 | 2023-12-28 | Elpiscience (Suzhou) Biopharma, Ltd. | Novel conjugate molecules targeting cd39 and tgfbeta |
| EP4291227A2 (en) * | 2021-02-15 | 2023-12-20 | Takeda Pharmaceutical Company Limited | Cell therapy compositions and methods for modulating tgf-b signaling |
| CN116917334B (zh) * | 2021-02-22 | 2026-02-06 | 浙江道尔生物科技有限公司 | 一种具有抗癌活性的多结构域融合蛋白 |
| CN112979802B (zh) * | 2021-04-21 | 2021-08-03 | 上海普铭生物科技有限公司 | 抗人il-33单克隆抗体及其应用 |
| CN113249330A (zh) * | 2021-05-20 | 2021-08-13 | 深圳市先康达生命科学有限公司 | 免疫细胞及其应用 |
| WO2022258622A1 (en) | 2021-06-07 | 2022-12-15 | Ares Trading S.A. | Combination treatment of cancer |
| WO2023034742A1 (en) * | 2021-08-30 | 2023-03-09 | The Board Of Trustees Of The Leland Stanford Junior University | T cells with cell-surface expression of adenosine deaminase and uses thereof |
| JP2024533109A (ja) * | 2021-08-31 | 2024-09-12 | ザ テキサス エーアンドエム ユニヴァーシティ システム | キメラ抗原受容体（ｃａｒ）ｔ細胞療法プラットフォーム |
| US20240391990A1 (en) * | 2021-09-03 | 2024-11-28 | Nan TANG | Bi-functional fusion protein and uses thereof |
| WO2023086920A2 (en) * | 2021-11-12 | 2023-05-19 | Georgia Tech Research Corporation | Adenosine deaminase 2 compositions and methods for using same |
| CN118339187A (zh) * | 2021-12-31 | 2024-07-12 | 上海宏成药业有限公司 | 抗pd-1抗体及其用途 |
| CN114540311A (zh) * | 2022-02-24 | 2022-05-27 | 深圳市先康达生命科学有限公司 | 一种免疫细胞及其应用 |
| CN116041539B (zh) * | 2022-10-31 | 2023-07-21 | 山东博安生物技术股份有限公司 | Il-2突变体免疫缀合物 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5595756A (en) * | 1993-12-22 | 1997-01-21 | Inex Pharmaceuticals Corporation | Liposomal compositions for enhanced retention of bioactive agents |
| EP0973888A1 (en) | 1997-02-06 | 2000-01-26 | Human Genome Sciences, Inc. | Dendritic cell-derived growth factor |
| JP2001515360A (ja) | 1997-04-18 | 2001-09-18 | バイオジェン，インコーポレイテッド | ▲ＩＩ▼型ＴＧＦ−βレセプター／免疫グロブリン定常領域融合タンパク質 |
| ES2350687T3 (es) | 2002-07-03 | 2011-01-26 | Ono Pharmaceutical Co., Ltd. | Composiciones de inmunopotenciación. |
| RU2494107C2 (ru) * | 2005-05-09 | 2013-09-27 | Оно Фармасьютикал Ко., Лтд. | Моноклональные антитела человека к белку программируемой смерти 1 (pd-1) и способы лечения рака с использованием анти-pd-1-антител самостоятельно или в комбинации с другими иммунотерапевтическими средствами |
| HRP20131167T1 (hr) | 2007-06-18 | 2014-01-03 | Merck Sharp & Dohme B.V. | Antitijela za humani receptor programirane smrti pd-1 |
| US20110245174A1 (en) * | 2008-08-21 | 2011-10-06 | Peter Artymiuk | Glp-1 fusion polypeptides |
| CA3083324A1 (en) * | 2010-03-05 | 2011-09-09 | The Johns Hopkins University | Compositions and methods for targeted immunomodulatory antibodies and fusion proteins |
| US20150086584A1 (en) | 2012-03-22 | 2015-03-26 | University Of Miami | Multi-specific binding agents |
| CN110563850A (zh) | 2012-04-30 | 2019-12-13 | 比奥孔有限公司 | 靶向/免疫调节性融合蛋白及其制造方法 |
| WO2013169693A1 (en) * | 2012-05-09 | 2013-11-14 | Bristol-Myers Squibb Company | Methods of treating cancer using an il-21 polypeptide and an anti-pd-1 antibody |
| US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
| EP3783098A1 (en) | 2013-05-14 | 2021-02-24 | Board Of Regents, The University Of Texas System | Human application of engineered chimeric antigen receptor (car) t-cells |
| CA2920113A1 (en) * | 2013-08-20 | 2015-02-26 | Merck Sharp & Dohme Corp. | Treating cancer with a combination of a pd-1 antagonist and dinaciclib |
| CA2921805C (en) | 2013-08-22 | 2023-03-07 | Acceleron Pharma, Inc. | Tgf-beta receptor type ii variants and uses thereof |
| TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對ｐｄ-１的人類抗體 |
| US9676863B2 (en) | 2014-02-10 | 2017-06-13 | Merck Patent Gmbh | Targeted TGFβ inhibitors |
| KR20160145802A (ko) | 2014-04-23 | 2016-12-20 | 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 | 요법에 사용하기 위한 키메라 항원 수용체 (car) 및 이의 제조 방법 |
| ES2753391T3 (es) | 2014-10-14 | 2020-04-08 | Halozyme Inc | Composiciones de adenosina desaminasa 2 (ADA2), variantes de la misma y métodos de uso de las mismas |
| KR20190003938A (ko) | 2016-02-25 | 2019-01-10 | 셀 메디카 스위처란트 아게 | 면역치료를 위한 변형된 세포 |
| EP3487998B1 (en) * | 2016-07-19 | 2023-07-12 | Brandeis University | Compositions and methods for identifying rna binding polypeptide targets |
| EP3497130B1 (en) | 2016-08-12 | 2021-10-27 | Merck Patent GmbH | Combination therapy for cancer |
| CN118307682A (zh) | 2016-09-27 | 2024-07-09 | 埃皮辛特瑞柯斯公司 | 免疫调节性融合蛋白 |
| WO2018129331A1 (en) | 2017-01-07 | 2018-07-12 | Merck Patent Gmbh | Dosing regimens and dosage forms for targeted tgf-b inhibition |
| LT3628049T (lt) | 2017-05-04 | 2023-08-25 | Acceleron Pharma Inc. | Tgf-beta ii tipo receptoriaus sulieti baltymai ir jų panaudojimo būdai |
| JP7340458B2 (ja) | 2017-05-09 | 2023-09-07 | アメリカ合衆国 | Ｈｐｖ＋悪性腫瘍を有する患者におけるｐｄｌ１とｔｇｆベータの遮断の組み合わせ |
| AU2018264455B2 (en) | 2017-05-12 | 2024-12-12 | Jiangsu Hengrui Medicine Co., Ltd. | Fusion protein containing TGF-beta receptor and medicinal uses thereof |
| CN112512576A (zh) | 2018-05-04 | 2021-03-16 | 默克专利有限公司 | PD-1/PD-L1、TGFβ和DNA-PK联合抑制用于治疗癌症 |
| WO2020118094A1 (en) * | 2018-12-06 | 2020-06-11 | Guangdong Tcrcure Biopharma Technology Co., Ltd. | Combinational tcr-t cell therapy targeting tumor antigens, tgf-beta, and immune checkpoints |
| CN109913425B (zh) * | 2019-03-22 | 2021-05-11 | 中国人民解放军总医院第五医学中心 | 一种重组流感病毒拯救方法及其在肿瘤治疗中的应用 |
| CN114555099A (zh) * | 2019-06-23 | 2022-05-27 | 广东天科雅生物医药科技有限公司 | 抗alpp car-t细胞疗法 |
-
2019
- 2019-07-09 WO PCT/US2019/041085 patent/WO2020014285A2/en not_active Ceased
- 2019-07-09 SG SG11202100208VA patent/SG11202100208VA/en unknown
- 2019-07-09 EP EP19834221.4A patent/EP3820496A4/en active Pending
- 2019-07-09 AU AU2019301070A patent/AU2019301070B2/en active Active
- 2019-07-09 JP JP2021500735A patent/JP7617839B2/ja active Active
- 2019-07-09 US US16/506,981 patent/US11535669B2/en active Active
- 2019-07-09 CN CN201980058963.8A patent/CN112672753B/zh active Active
- 2019-07-09 CA CA3105750A patent/CA3105750A1/en active Pending
- 2019-07-09 KR KR1020217003783A patent/KR20210042909A/ko not_active Ceased
- 2019-07-09 CN CN202510846429.0A patent/CN120775065A/zh active Pending
-
2021
- 2021-01-05 IL IL279965A patent/IL279965A/en unknown
- 2021-01-19 ZA ZA2021/00390A patent/ZA202100390B/en unknown
-
2022
- 2022-11-23 US US18/058,364 patent/US20240141045A1/en active Pending
-
2023
- 2023-01-10 ZA ZA2023/00423A patent/ZA202300423B/en unknown
-
2025
- 2025-01-07 JP JP2025002212A patent/JP2025063123A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021531754A5 (https=) | ||
| JPWO2020014285A5 (https=) | ||
| JP7450684B2 (ja) | 制約されたｃｄ３結合を有する多重特異性ポリペプチド構築物およびそれを使用する方法 | |
| Jin et al. | Emerging new therapeutic antibody derivatives for cancer treatment | |
| US20230203173A1 (en) | Tumor necrosis factor (tnf) superfamily receptor igm antibodies and uses thereof | |
| JP2025063123A5 (https=) | ||
| US20180127502A1 (en) | Novel pd-1 immune modulating agents | |
| WO2006020258A2 (en) | Novel tetravalent bispecific antibody | |
| CN101432015A (zh) | 功能性抗体 | |
| JP2019528683A (ja) | 多量体ｇｉｔｒ結合分子及びその使用 | |
| JP2021512151A5 (https=) | ||
| JP7754506B2 (ja) | ポリオウイルス受容体（ｐｖｒ）に対する抗体およびその使用 | |
| JP2024518200A (ja) | Ｔ細胞リダイレクト治療薬及び抗ｃｄ４４治療薬を含む組成物 | |
| Müller et al. | Bispecific Antibodies | |
| CA3082036C (en) | MONOSPACTIC AND BISPACTIC PROTEINS WITH IMMUNE CHECKPOINT REGULATION ROLE FOR CANCER TREATMENT | |
| JP2021520201A (ja) | 抗ｃｄ２７抗体およびその使用 | |
| CA3147420A1 (en) | Anti-egfr/anti-4-1bb bispecific antibody and use thereof | |
| CA3207791A1 (en) | Anti-cd112r antibody and use thereof | |
| Schaedel et al. | Antibodies and their fragments as anti-cancer agents | |
| TW202542198A (zh) | Cd137結合分子及其用途 | |
| Müller et al. | Bispecific antibodies | |
| EP4667491A1 (en) | Anti-cntn4 antibody and uses thereof | |
| WO2023178253A2 (en) | Use of a multimeric anti-pd-l1 binding molecule in combination with a monoclonal antibody therapy | |
| WO2024037628A1 (zh) | 一种双特异性抗体及其应用 | |
| CA3205494A1 (en) | Bispecific antibody for specifically neutralizing tgf-.beta. signal of helper t cell, and pharmaceutical combination and use thereof |